Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 11, 2010 - Issue 4
Submit an article Journal homepage
222
Views
21
CrossRef citations to date
0
Altmetric
Drug Evaluations

Role of ribavirin in HCV treatment response: now and in the future

Mamta K Jain UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Texas, 75390-9113, USA +1 214 648 9914; +1 214 648 2741; [email protected]
, MD MPH &
Cindy Zoellner Parkland Health and Hospital System, 5201 Harry Hines Blvd., Dallas, Texas, 75235, USA
, PharmD
Pages 673-683 | Published online: 17 Feb 2010

Bibliography

  • World Health Organization Global Alert and Response. Hepatitis C. Available from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index3.html. [Accessed 24 October 2009]
  • Armstrong GL, Wasley A, Simard EP, The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705-14
  • Di Bisceglie AM, Lyra AC, Schwartz M, Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003;98(9):2060-3
  • Zein NN, Rakela J, Krawitt EL, Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996;125(8):634-9
  • Benhamou Y, Afdhal NH, Nelson DR, A Phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naive patients with chronic hepatitis C: ViSER1 results. Hepatology 2009;50(3):717-26
  • Lin CC, Lourenco D, Xu G, Yeh LT. Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver. Antimicrob Agents Chemother 2004;48(5):1872-5
  • Poordad F, Lawitz E, Hassanein T, Sustained virologic response (SVR) results for weight-based-tarivavirin versus weight-based-ribavirin, in naive chronic-hepatitis C, genotype 1 patients [abstract 65]. Hepatology 2009;50(4):334A
  • Wu JZ, Lin CC, Hong Z. Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J Antimicrob Chemother 2003;52(4):543-6
  • Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004;432(7019):922-4
  • Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int 2008;28(10):1332-43
  • Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5(3):215-29
  • Shiina M, Kobayashi K, Satoh H, Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards Type 1 in chronic hepatitis C. J Gastroenterol Hepatol 2004;19(5):558-64
  • Levy GA, Adamson G, Phillips MJ, Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity. Hepatology 2006;43(3):581-91
  • Ning Q, Brown D, Parodo J, Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160(7):3487-93
  • Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 2006;63(7-8):832-42
  • Scheidel LM, Durbin RK, Stollar V. Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 1987;158(1):1-7
  • Sintchak MD, Nimmesgern E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000;47(2-3):163-84
  • Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002;35(5):1002-9
  • Vo NV, Young KC, Lai MM. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 2003;42(35):10462-71
  • Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001;276(49):46094-8
  • Asahina Y, Izumi N, Enomoto N, Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 2005;43(4):623-9
  • Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuan R. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol 2009;83(11):5760-4
  • Hofmann WP, Polta A, Herrmann E, Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 2007;132(3):921-30
  • Pawlotsky JM, Dahari H, Neumann AU, Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126(3):703-14
  • Lutchman G, Danehower S, Song BC, Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007;132(5):1757-66
  • Liu WL, Su WC, Cheng CW, Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus. J Infect Dis 2007;196(3):425-34
  • Su WC, Liu WL, Cheng CW, Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. FEBS Lett 2009;583(17):2793-8
  • Feld JJ, Nanda S, Huang Y, Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007;46(5):1548-63
  • Thomas E, Feld JJ, Fried MW, Liang TJ. A novel innate immune mechanism of action of ribavirin in antiviral therapy [abstract 124]. Hepatology 2009;50(4):362A
  • Ibarra KD, Pfeiffer JK. Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. J Virol 2009;83(9):4538-47
  • Jen J, Laughlin M, Chung C, Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002;72(4):349-61
  • Preston SL, Drusano GL, Glue P, Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 1999;43(10):2451-6
  • Patil SD, Ngo LY, Glue P, Unadkat JD. Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharm Res 1998;15(6):950-2
  • Wade JR, Snoeck E, Duff F, Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006;62(6):710-4
  • Copegus. [package insert]. Nutley, New Jersey: Roche Laboratories, Inc. 2009
  • Loustaud-Ratti V, Alain S, Rousseau A, Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008;47(5):1453-61
  • Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002;24(6):701-8
  • Maeda Y, Kiribayashi Y, Moriya T, Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 2004;26(1):9-15
  • Toyoda H, Kumada T, Kiriyama S, Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin. J Viral Hepat 2008;15(9):651-8
  • Jen JF, Glue P, Gupta S, Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000;22(5):555-65
  • Dahari H, Markatou M, Zeremski M, Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007;47(1):23-30
  • Nicot F, Legrand-Abravanel F, Lafont T, Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol 2008;80(9):1523-9
  • Larrat S, Stanke-Labesque F, Plages A, Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003;47(1):124-9
  • Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998;123(8):1587-92
  • Shulman NR. Assessment of hematological effects of ribavirin in humans. New York: Academic Press, 1984
  • Homma M, Matsuzaki Y, Inoue Y, Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004;2(4):337-9
  • Tod M, Farcy-Afif M, Stocco J, Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Clin Pharmacokinet 2005;44(4):417-28
  • Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004;11(1):84-7
  • Bodenheimer HC Jr, Lindsay KL, Davis GL, Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26(2):473-7
  • Dusheiko G, Main J, Thomas H, Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25(5):591-8
  • Hoofnagle JH, Lau D, Conjeevaram H, Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat 1996;3(5):247-52
  • Zoulim F, Haem J, Ahmed SS, Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat 1998;5(3):193-8
  • Di Bisceglie AM, Conjeevaram H, Fried MW, Ribavirin as therapy for chronic hepatitis C. Ann Intern Med 1995;123(12):897-903
  • Barbaro G, Di Lorenzo G, Soldini M, Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators. J Hepatol 2000;33(3):448-55
  • McHutchison JG, Gordon SC, Schiff ER, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485-92
  • Poynard T, Marcellin P, Lee SS, Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352(9138):1426-32
  • Fried MW, Shiffman ML, Reddy KR, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
  • Manns MP, McHutchison JG, Gordon SC, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65
  • Hadziyannis SJ, Sette H Jr, Morgan TR, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-55
  • Jacobson IM, Brown RS Jr, Freilich B, Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46(4):971-81
  • Mangia A, Santoro R, Minerva N, Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352(25):2609-17
  • Shiffman ML, Suter F, Bacon BR, Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357(2):124-34
  • Ferenci P, Brunner H, Laferl H, A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008;47(6):1816-23
  • von Wagner M, Huber M, Berg T, Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129(2):522-7
  • Hiramatsu N, Oze T, Yakushijin T, Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat 2009;16(8):586-94
  • Reddy KR, Shiffman ML, Morgan TR, Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5(1):124-9
  • Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007;46(6):1688-94
  • Reddy RK, Shiffman ML, Rodriguez-Torres M, Standard versus higher induction doses of peginterferon alfa-2a (40KD) and/or higher ribavirin (RBV) in HCV G1 patietns with high viral load and body weight >85 kg final results of the progress study [abstract 61]. Hepatology 2009;50(4):331A
  • Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005;41(2):275-9
  • Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med 2000;160(22):3365-73
  • Thomas DL, Astemborski J, Rai RM, The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284(4):450-6
  • Beld M, Penning M, Lukashov V, Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 1998;244(2):504-12
  • Graham CS, Baden LR, Yu E, Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33(4):562-9
  • Lohse N, Hansen AB, Pedersen G, Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146(2):87-95
  • Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357(9252):280-1
  • Moreno A, Quereda C, Moreno L, High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 2004;9(1):133-8
  • Videx. [package insert]. Princeton, NJ: Briston-Myers Squibb Company 2007
  • Afdhal NH, Dieterich DT, Pockros PJ, Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126(5):1302-11
  • Behler CM, Vittinghoff E, Lin F, Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV Type 1-coinfected subjects. Clin Infect Dis 2007;44(10):1375-83
  • Brillanti S, Buonfiglioli F, Feletti V, Ribavirin priming enhancing efficacy of chronic hepatitis C re-treatment in patients who had not responded to previous combination therapy [abstract 32]. Hepatology 2009;50(4):317A
  • Yoffe B, Gasitashvili K, Khaoustov V. Pilot study of lead-in nitazoxanide plus pegylated alpha-2a interferon and ribavirin in HCV-genotype1 nonresponders with cirrhosis:interim analysis [abstract 1580]. Hepatology 2009;50(4):1034A
  • Elazar M, Liu M, McKenna SA, The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology 2009;137(5):1827-35
  • Reesink HW, Zeuzem S, Weegink CJ, Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131(4):997-1002
  • McHutchison JG, Everson GT, Gordon SC, Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360(18):1827-38
  • Hezode C, Forestier N, Dusheiko G, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839-50
  • McHutchison JG, Manns MP, Muir A, PROVE 3 final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy [abstract 66]. Hepatology 2009;50(4):334A
  • Marcellin P, Forns X, Goeser T, Virological analysis of patients receiving telaprevir administered q8h or q12h with peginterferon-alfa-2a or alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C: study C208 [abstract 194]. Hepatology 2009;50(4):395A
  • Kwo P, Lawitz EJ, McCone J, Final results SVR 24 boceprevir plus PegIFN alpha-2b/ribavirin HCV 1 treatment naive patients. 44th Annual Meeting of the European Association for the Study of the Liver; 2009 April 22-26, 2009; Copenhagen, Denmark; 2009
  • Gane EJ, Roberts SK, Stedman CA, Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM-1 [abstract 193]. Hepatology 2009;50(4):394A

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.